MESO Q2 2017 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$550,000-86.3% YoY

Gross Profit

-$3M-589.1% margin

Operating Income

-$23M-4154.7% margin

Net Income

-$20M-3645.6% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+39.2%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$525,000

Balance Sheet

Total Assets

$661M

Total Liabilities

$150M

Stockholders' Equity

$511M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$550,000	$4M	-86.3%
Gross Profit	-$3M	-$4M	+21.1%
Operating Income	-$23M	-$22M	-4.8%
Net Income	-$20M	-$22M	+10.2%